Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goki Suda

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 31, 2020
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19Goki Suda, Koji Ogawa, Megumi Kimura, et al.
Frontiers in Nutrition|March 6, 2026
Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver diseaseTakatsugu Tanaka, Goki Suda, Masatsugu Ohara, et al.
Journal of Virology|April 15, 2011
Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91Yusuke Funaoka, Naoya Sakamoto, Goki Suda, et al.
Internal Medicine (Tokyo, Japan)|December 21, 2018
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor TreatmentGoki Suda, Masato Nakai, Takuya Sho, et al.
Cancer Biology & Therapy|April 22, 2015
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transitionFumiyuki Sato, Yoshimasa Kubota, Mitsuteru Natsuizaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 24, 2008
Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replicationYuko Sekine-Osajima, Naoya Sakamoto, Mina Nakagawa, et al.
Drugs in R&D|June 3, 2017
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular CarcinomaTakuya Sho, Mitsuru Nakanishi, Kenichi Morikawa, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2018
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three CasesTakuya Sho, Goki Suda, Megumi Kimura, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|October 26, 2020
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinomaTaku Shigesawa, Goki Suda, Megumi Kimura, et al.
Cancers|July 24, 2021
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRIAkinori Kubo, Goki Suda, Megumi Kimura, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 31, 2020
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19Goki Suda, Koji Ogawa, Megumi Kimura, et al.
Frontiers in Nutrition|March 6, 2026
Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver diseaseTakatsugu Tanaka, Goki Suda, Masatsugu Ohara, et al.
Journal of Virology|April 15, 2011
Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91Yusuke Funaoka, Naoya Sakamoto, Goki Suda, et al.
Internal Medicine (Tokyo, Japan)|December 21, 2018
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor TreatmentGoki Suda, Masato Nakai, Takuya Sho, et al.
Cancer Biology & Therapy|April 22, 2015
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transitionFumiyuki Sato, Yoshimasa Kubota, Mitsuteru Natsuizaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 24, 2008
Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replicationYuko Sekine-Osajima, Naoya Sakamoto, Mina Nakagawa, et al.
Drugs in R&D|June 3, 2017
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular CarcinomaTakuya Sho, Mitsuru Nakanishi, Kenichi Morikawa, et al.
Internal Medicine (Tokyo, Japan)|November 20, 2018
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three CasesTakuya Sho, Goki Suda, Megumi Kimura, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|October 26, 2020
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinomaTaku Shigesawa, Goki Suda, Megumi Kimura, et al.
Cancers|July 24, 2021
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRIAkinori Kubo, Goki Suda, Megumi Kimura, et al.
Pageof 15